Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Avenue Therapeutics, Inc. (ATXI)

1.38   -0.17 (-10.97%) 01-27 16:00
Open: 1.54 Pre. Close: 1.55
High: 1.6 Low: 1.33
Volume: 1,018,935 Market Cap: 7(M)

Technical analysis

as of: 2023-01-27 4:42:40 PM
Overall:       
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 2.16     One year: 2.74
Support: Support1: 1.05    Support2: 0.88
Resistance: Resistance1: 1.85    Resistance2: 2.34
Pivot: 1.41
Moving Average: MA(5): 1.53     MA(20): 1.36
MA(100): 2.66     MA(250): 4.47
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 32.5     %D(3): 36.5
RSI: RSI(14): 47.9
52-week: High: 18.75  Low: 0.24
Average Vol(K): 3-Month: 892 (K)  10-Days: 3,335 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ATXI ] has closed above bottom band by 46.4%. Bollinger Bands are 71.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 62 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.6 - 1.61 1.61 - 1.62
Low: 1.31 - 1.32 1.32 - 1.33
Close: 1.36 - 1.38 1.38 - 1.39

Company Description

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Headline News

Sat, 28 Jan 2023
Ameren Co. (NYSE:AEE) Shares Sold by AIA Group Ltd - MarketBeat

Tue, 24 Jan 2023
Is Avenue Therapeutics Inc (ATXI) Stock a Bad Value? - InvestorsObserver

Wed, 18 Jan 2023
Pre-market Movers: FUV, CYAD, ATXI, CSSE, PXMD… - RTTNews

Tue, 17 Jan 2023
U.S. stocks mixed at close of trade; Dow Jones Industrial Average ... - Investing.com

Tue, 17 Jan 2023
Avenue Therapeutics Inc (ATXI) has gained 7.38% Tuesday In Premarket Trading - InvestorsObserver

Tue, 17 Jan 2023
Lightning Alerts: SOUN, ATER, TMPO, and ATXI - Raging Bull - RagingBull

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 5 (M)
Shares Float 4 (M)
% Held by Insiders 7.6 (%)
% Held by Institutions 12.8 (%)
Shares Short 126 (K)
Shares Short P.Month 83 (K)

Stock Financials

EPS -0.32
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.03
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -499.4
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -5 (M)
Levered Free Cash Flow -3 (M)

Stock Valuations

PE Ratio -4.46
PEG Ratio 0
Price to Book value -46
Price to Sales 0
Price to Cash Flow -1.43

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.